Dr. Kumar on Studies Investigating Venetoclax in Multiple Myeloma

Shaji K. Kumar, MD
Published: Monday, Mar 27, 2017



Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myelomacl-2 protein.

There are 2 studies looking at the efficacy of venetoclax in patients with multiple myeloma, explains Kumar. One study, which enrolled 66 patients, looked at venetoclax alone, where the maximum dose was determined as well as an overall response rate of 21% in the advanced relapsed patient population. The median progression-free survival for these patients was nearly 12 months.

Additional molecular testing has been done to identify the cohort of patients who are most likely to respond to venetoclax. This identified a group where the response rate was 85%, states Kumar.
 
SELECTED
LANGUAGE


Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myelomacl-2 protein.

There are 2 studies looking at the efficacy of venetoclax in patients with multiple myeloma, explains Kumar. One study, which enrolled 66 patients, looked at venetoclax alone, where the maximum dose was determined as well as an overall response rate of 21% in the advanced relapsed patient population. The median progression-free survival for these patients was nearly 12 months.

Additional molecular testing has been done to identify the cohort of patients who are most likely to respond to venetoclax. This identified a group where the response rate was 85%, states Kumar.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x